首页> 外文OA文献 >Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11
【2h】

Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11

机译:利用载有动质体膜蛋白11的PLGA纳米颗粒开发新型的针对利什曼病的免疫策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Vaccine development has been a priority in the fight against leishmaniases, which are vector-borne diseases caused by Leishmania protozoa. Among the different immunization strategies employed to date is inoculation of plasmid DNA coding for parasite antigens, which has a demonstrated ability to induce humoral and cellular immune responses. In this sense, inoculation of plasmid DNA encoding Leishmania kinetoplasmid membrane protein-11 (KMP-11) was able to confer protection against visceral leishmaniasis. However, recently the use of antigen delivery systems such as poly(lactic-co-glycolic acid) (PLGA) nanoparticles has also proven effective for eliciting protective immune responses. Methods: In the present work, we tested two immunization strategies with the goal of obtaining protection, in terms of lesion development and parasite load, against cutaneous leishmaniasis caused by L. braziliensis. One strategy involved immunization with plasmid DNA encoding L. infantum chagasi KMP-11. Alternatively, mice were primed with PLGA nanoparticles loaded with the recombinant plasmid DNA and boosted using PLGA nanoparticles loaded with recombinant KMP-11. Results: Both immunization strategies elicited detectable cellular immune responses with the presence of both proinflammatory and anti-inflammatory cytokines; mice receiving the recombinant PLGA nanoparticle formulations also demonstrated anti-KMP-11 IgG1 and IgG2a. Mice were then challenged with L. braziliensis, in the presence of sand fly saliva. Lesion development was not inhibited following either immunization strategy. However, immunization with PLGA nanoparticles resulted in a more prominent reduction in parasite load at the infection site when compared with immunization using plasmid DNA alone. This effect was associated with a local increase in interferon-gamma and in tumor necrosis factor-alpha. Both immunization strategies also resulted in a lower parasite load in the draining lymph nodes, albeit not significantly. Conclusion: Our results encourage the pursuit of immunization strategies employing nanobased delivery systems for vaccine development against cutaneous leishmaniasis caused by L. braziliensis infection. © 2012 Santos et al, publisher and licensee Dove Medical Press Ltd.
机译:背景:疫苗开发一直是防治利什曼原虫病的优先事项,利什曼原虫病是由利什曼原虫引起的媒介传播疾病。迄今为止采用的不同免疫策略之一是接种编码寄生虫抗原的质粒DNA,具有证明的诱导体液和细胞免疫应答的能力。从这个意义上讲,编码利什曼原虫运动质粒膜蛋白11(KMP-11)的质粒DNA的接种能够赋予针对内脏利什曼病的保护作用。但是,最近也证明了使用抗原递送系统,例如聚乳酸-乙醇酸(PLGA)纳米颗粒,可以有效地引发保护性免疫反应。方法:在目前的工作中,我们测试了两种免疫策略,目的是在损伤发展和寄生虫负荷方面获得针对由巴西乳杆菌引起的皮肤利什曼病的保护。一种策略涉及用编码婴儿痢疾乳杆菌KMP-11的质粒DNA进行免疫。备选地,用装载有重组质粒DNA的PLGA纳米颗粒引发小鼠,并用装载有重组KMP-11的PLGA纳米颗粒加强免疫。结果:两种免疫策略在存在促炎和抗炎细胞因子的情况下均可引发可检测的细胞免疫反应。接受重组PLGA纳米颗粒制剂的小鼠也表现出抗KMP-11 IgG1和IgG2a。然后在沙蝇唾液存在下用巴西乳杆菌攻击小鼠。两种免疫策略均未抑制病变的发展。但是,与仅使用质粒DNA进行免疫相比,使用PLGA纳米粒子进行免疫可导致感染部位的寄生虫负荷更加显着降低。这种作用与干扰素-γ和肿瘤坏死因子-α的局部增加有关。两种免疫策略也导致引流淋巴结的寄生虫负荷降低,尽管效果不明显。结论:我们的结果鼓励采用基于纳米的递送系统的免疫策略,以开发针对巴西乳杆菌感染引起的皮肤利什曼病的疫苗。 ©2012 Santos等人,出版商和被许可人Dove Medical Press Ltd.。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号